SMMTDown −16.5%Summit Therapeutics
Why Summit Therapeutics (SMMT) Stock Fell 16.5% Today
Summit Therapeutics (SMMT) fell 16.5% after it said the FDA issued a Complete Response Letter on its application for ivonescimab in lung cancer.
Movers
Monday
Latest trading day covered
Summit Therapeutics
Every big move we have covered on Summit Therapeutics, newest first. Each story gives the answer first and links to the filings and releases behind it.
Last covered move
Close that day$11.82
Figures are from the day of the story, not live quotes.
Why it moved that dayNewest first. Moves and closes are for the day each story covers.
SMMTDown −16.5%Summit Therapeutics
Summit Therapeutics (SMMT) fell 16.5% after it said the FDA issued a Complete Response Letter on its application for ivonescimab in lung cancer.
SMMT CGON HTHT TSN
Summit Therapeutics fell 16.5% after an FDA Complete Response Letter, and CG Oncology rose 14.0% after trial results. H World and Tyson Foods rose.
Summit Therapeutics Inc. filings with the SEC from the last 180 days, newest first. We wrote about one of them.
Filings come straight from the SEC's EDGAR database and are listed automatically. They are not written or checked by us. Fetched .
All 28 filings, including insider trade reports. Insider reports filed on the same day are grouped into one row.
Insider trade reports (3)
Form 4Quarterly report
10-QResults announced (earnings release)
8-KAlso: charter, bylaws or fiscal year changed, shareholder vote results
Company update
8-KShare offering documents
424B7Proxy statement for the shareholder meeting
DEF 14AInsider trade report
Form 4Draft proxy statement
PRE 14AMajor agreement signed
8-KAlso: shares sold without registration, charter, bylaws or fiscal year changed, company update
Company update
8-KCompany update
8-KCompany update
8-KCompany update
8-KCompany update
8-KQuarterly report
10-QResults announced (earnings release)
8-KAlso: company update
Major agreement signed
8-KShare offering documents
424B5Company update
8-KShareholder vote results
8-KInsider trade reports (2)
Form 4Company update
8-KShare offering documents
424B5Share offering documents
S-3ASRInsider trade reports (3)
Form 4Company update
8-KCompany update
8-KShowing 23 key filings: company reports, results, annual and quarterly reports, proxies and offerings.
Quarterly report
10-QResults announced (earnings release)
8-KAlso: charter, bylaws or fiscal year changed, shareholder vote results
Company update
8-KShare offering documents
424B7Proxy statement for the shareholder meeting
DEF 14AMajor agreement signed
8-KAlso: shares sold without registration, charter, bylaws or fiscal year changed, company update
Company update
8-KCompany update
8-KCompany update
8-KCompany update
8-KCompany update
8-KQuarterly report
10-QResults announced (earnings release)
8-KAlso: company update
Major agreement signed
8-KShare offering documents
424B5Company update
8-KShareholder vote results
8-KCompany update
8-KShare offering documents
424B5Share offering documents
S-3ASRCompany update
8-KCompany update
8-KAs registered with the SEC
Other stocks in the same day's coverage
CG Oncology
CG Oncology (CGON) rose 14.0% after it said its Phase 3 bladder cancer trial PIVOT-006 met its primary endpoint.
Close $84.78
H World
H World (HTHT) rose 8.9% after the hotel group reported third quarter results and raised its 2026 revenue growth forecast to 9% to 10%.
Close $54.88
Tyson Foods
Tyson Foods (TSN) rose 8.7% after it reported fiscal fourth quarter results and forecast fiscal 2027 adjusted operating income of $1.7 billion to $2.15 billion.
Close $63.95
These stories explain past price moves using public sources. They are not investment advice. See our disclaimer.